FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading MOST POPULAR 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... May 13, 2019 FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... August 29, 2025 Leveraging Extensive Real-World Data to Systematically Identify Mutations that Predict the... July 11, 2022 Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival November 6, 2024 Load more HOT NEWS AI and remote monitoring are shaping a new patient journey in... Texting May Help Reduce Disparities in Colorectal Cancer Screening Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... Robin Williams Required Film Companies He Worked With To Hire Homeless...
